Powered by

After divestiture, all eyes on Pfizer's next move

Apr 23, 2012 - The Deal Pipeline
Mergers and Acquisitions

When the bell finally rang on the long-awaited divestiture of Pfizer Inc.'s nutrition business early Monday, the only thing that surprised observers was the high price tag. But what investors will likely watch with greater curiosity is where the drugmaker aims to go from here: Will it return to its old megamerger ways, or continue toward a breakup? Pfizer agreed to shed its nutrition business - which sells infant and toddler nutritional products - to Nestlé SA for $11.85 billion on Monday...